EVGN Evogene
Evogene earnings company data as of 4:49 AM ET 10/23
- 0 of 1 EPS beats
History
2 periods, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 19 Nov | EPS | — | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 18 Aug | EPS | -0.27 | -0.63 | Miss |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by EVGN's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $693K bought by 2 insiders
- None no sales outside a trading plan
- None no planned (10b5-1) sales
-
Gabi Tarcic Chief Development OfficerBuy$677 1,129 shares at $0.6000 New stakeTraded Jun 4 Filed Aug 26
-
Leon Recanati DirectorBuy$292K 460,000 shares at $0.6400 +52% to stakeTraded Aug 11 Filed Aug 13
-
Leon Recanati DirectorBuy$400K 800,000 shares at $0.5000 +954% to stakeTraded Aug 4 Filed Aug 5
SEC filings
Recent issuer filings from EDGAR, 25 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| SCHEDULE 13D/A | — | Filing Doc | |
| 6-K | Filing Doc | ||
| 6-K | Filing Doc | ||
| 6-K | Filing Doc | ||
| 6-K | Filing Doc | ||
| SCHEDULE 13D/A | — | Filing Doc | |
| SCHEDULE 13D/A | — | Filing Doc | |
| 6-K | Filing Doc | ||
| SCHEDULE 13D/A | — | Filing Doc | |
| 6-K | Filing Doc | ||
| 6-K | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13D/A | — | Filing Doc | |
| SCHEDULE 13D/A | — | Filing Doc | |
| SCHEDULE 13D | — | Filing Doc | |
| SCHEDULE 13D/A | — | Filing Doc | |
| 6-K | Filing Doc | ||
| SCHEDULE 13D/A | — | Filing Doc | |
| SCHEDULE 13D/A | — | Filing Doc | |
| 6-K | Filing Doc | ||
| 424B5 | Filing Doc | ||
| SCHEDULE 13D | — | Filing Doc | |
| 6-K | Filing Doc | ||
| 6-K | Filing Doc | ||
| 424B5 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.